The Oncotype DX® Breast Cancer Assay Results Change Treatment Decisions
Individualized Recurrence Score® (RS) results assess the potential benefit of chemotherapy and the likelihood of distant breast cancer recurrence
Treatment decisions were changed even when definitive treatment decisions had already been made for these patients
- 33% switched from chemotherapy + hormone therapy to hormone therapy alone based on a low Recurrence Score result
- 4% switched from hormonal therapy only to chemotherapy + hormonal therapy based on a high Recurrence Score result
Oncotype DX® is the only multigene breast cancer assay incorporated into 3 major clinical guidelines as an option to predict whether certain patients will benefit from chemotherapy including the National Comprehensive Cancer Network®(NCCN®), the American Society of Clinical Oncology® (ASCO®), and the St Gallen Consensus guidelines.